Incidence and costs of adverse drug reactions during hospitalisation. Computerised monitoring versus stimulated spontaneous reporting

Drug Safety

Volumn 22, Issue 2, 2000, Pages 161-168

  Dormann, Harald ^a   Muth Selbach, Uta ^a   Krebs, Sabine ^a   Criegee Rieck, Manfred ^a   Tegeder, Irmgard ^b   Thomas Schneider, H ^a   Hahn, Eckhart G ^a   Levy, Micha ^c   Brune, Kay ^a   Geisslinger, Gerd ^a,b  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b GOETHE UNIVERSITY   (Germany)

^c HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG;

ADOLESCENT; ADULT; ADVERSE DRUG REACTION; AGED; ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; COMPUTER ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST CONTROL; COST OF ILLNESS; DATA ANALYSIS; DRUG SURVEILLANCE PROGRAM; FEMALE; GASTROINTESTINAL DISEASE; HUMAN; INFECTION; LENGTH OF STAY; LIVER DISEASE; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; NEPHROTOXICITY; PRIORITY JOURNAL; PROSPECTIVE STUDY; SLEEP APNEA SYNDROME;

EID: 0033984792     PISSN: 01145916     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002018-200022020-00007     Document Type: Article

References (28)

1. 1. Leape LL, Brennan TA, Laird N, et al. The nature of adverse events in hospitalized patients: results of the Harvard Medical Practice Study II. N Engl J Med 1991 ; 324 (6): 377-84
2. 2. Bates DW, Cullen DJ, Laird N, et al. Incidence of adverse drug events and potential adverse drug events: implications for prevention: ADE Prevention Study Group [see comments]. JAMA 1995; 274(1): 29-34
3. 3. Levy M, Kletter-Hemo D, Nir I, et al. Drug utilization and adverse drug reactions in medical patients: comparison of two periods, 1969-72 and 1973-76. Isr J Med Sci 1977; 13(11): 1065-72
4. 4. Hutchinson TA, Flegel KM, Kramer MS, et al. Frequency, severity and risk factors for adverse drug reactions in adult out-patients: a prospective study. J Chronic Dis 1986; 39 (7): 533-42
5. 5. Hoigne R, Lawson DH, Weber E. Risk factors for adverse drug reactions - epidemiological approaches. Eur J Clin Pharmacol 1990; 39 (4): 321-5
6. 6. Inman WH. Under-reporting of adverse drug reactions [letter]. BMJ 1985; 290 (6478): 1355
7. 7. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies [see comments]. JAMA 1998; 279 (15): 1200-5
8. 8. Hallas J, Harvald B, Gram LF, et al. Drug related hospital admissions: the role of definitions and intensity of data collection, and the possibility of prevention. J Intern Med 1990; 228 (2): 83-90
9. 9. Hallas J, Gram LF, Grodum E, et al. Drug related admissions to medical wards: a population based survey. Br J Clin Pharmacol 1992; 33 (1):61-8
10. 10. Levy M, Kewitz H, Altwein W, et al. Hospital admissions due to adverse drug reactions: a comparative study from Jerusalem and Berlin. Eur J Clin Pharmacol 1980; 17 (1): 25-31
11. 11. Ibanez L, Laporte JR, Carne X. Adverse drug reactions leading to hospital admission. Drug Saf 1991; 6 (6): 450-9
12. 12. Classen DC, Pestotnik SL, Evans RS, et al. Adverse drug events in hospitalized patients. Excess length of stay, extra costs, and attributable mortality [see comments]. JAMA 1997; 277 (4): 301-6
13. 13. Evans RS, Pestotnik SL, Classen DC, et al. Preventing adverse drug events in hospitalized patients. Ann Pharmacother 1994; 28 (4); 523-7
14. 14. Meyboom RH, Egberts AC, Edwards IR, et al. Principles of signal detection in pharmacovigilance. Drug Saf 1997; 16 (6): 355-65
15. 15. Schoenemann J, Munter KH, Enayati-Kashani S. Unwanted drug effects in clinical practice [in German]. Dtsch Med Wochenschr 1998; 123 (15): 448-52
16. 16. Jha AK, Kuperman GJ, Teich JM, et al. Identifying adverse drug events: development of a computer-based monitor and comparison with chart review and stimulated voluntary report. J Am Med Inform Assoc 1998; 5 (3): 305-14
17. 17. Anderson JG, Jay SJ, Anderson M, et al. Evaluating the potential effectiveness of using computerized information systems to prevent adverse drug events. Proc AM1A Annu Fall Symp 1997: 228-32
18. 18. Levy M, Azaz-LivshitsT, Sudan B, et al. Computerized surveillance of adverse drug reactions in hospital: implementation. Eur J Clin Pharmacol 1999; 54 (11): 887-92
19. 19. World Health Organization. International drug monitoring: the role of the hospital. WHO Tech Rep Ser 1969; No. 425
20. 20. Azaz-Livshits T, Levy M, Sudan B, et al. Computerized surveillance of adverse drug reactions in hospital: pilot study. Br J Clin Pharmacol 1998; 45: 309-14
21. 21. Naranjo CA, Busto U, Sellers EM, at al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981; 30 (2): 239-45
22. 22. Rieder MJ. Mechanisms of unpredictable adverse drug reactions. Drug Saf 1994; 11 (3): 196-212
23. 23. Tegeder I, Levy M, Muth-Selbach U, et al. Retrospective analysis of the frequency and recognition of adverse drug reac-tions by means of automatically recorded laboratory signals. Br J Clin Pharmacol 1999; 47 (5): 557-64
24. 24. Joint Commission on Accreditation of Healthcare Organizations. Accreditation manual for hospitals. Chicago: Joint Commission on Accreditation of Healthcare Organizations, 1991
25. 25. Classen DC, Pestotnik SL, Evans RS, et al. Computerized surveillance of adverse drug events in hospital patients [erratum JAMA 1992; 267 (14): 1922] [see comments]. JAMA 1991; 266 (20): 2847-51
26. 26. Bates DW, Spell N, Cullen DJ, et al. The costs of adverse drug events in hospitalized patients: Adverse Drug Events Prevention Study Group [see comments]. JAMA 1997; 277 (4): 307-11
27. 27. Moore N, Briffaut C, Noblet C, et al. Indirect drug-related costs [letter]. Lancet 1995; 345 (8949): 588-9
28. 28. Evans RS, Classen DC, Stevens LE, et al. Using a hospital information system to assess the effects of adverse drug events. Proc Annu Symp Comput Appl Med Care 1993: 161-5